4 results
The primary objective of this study is to investigate if single-inhaler triple therapy (SITT, in this study Trimbow®) is superior to multi-inhaler triple therapy (MITT, in this study Bevespi® and Qvar®) in terms of adherence to inhaled…
* To assess the safety and tolerability of Ampligen administered intranasally in a dosing schedule for 13 days (7 doses) in healthy subjects.* To characterize the mucosal immune response following Ampligen administration over time.
To assess the efficacy of different top covers of inlays worn in orthopaedic footwear on the plantar pressure and patient satisfaction in diabetic patients at risk for foot ulceration.
The primary objective of the safety run-in (phase Ib) is to determine the safety of combination therapy with durvalumab and rintatolimod. The primary objective of the phase II trial is to determine the clinical benefit rate of combination therapy…